Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 645 Pancreatic Neoplasms 392 Carcinoma, Hepatocellular 308 Stomach Neoplasms 252 Rectal Neoplasms 182 Colonic Neoplasms 182 Esophageal Neoplasms 171 Carcinoma, Non-Small-Cell Lung 169 Breast Neoplasms 150 Neoplasms 135 Neoplasm Metastasis 131 Ovarian Neoplasms 123 Cholangiocarcinoma 112 Lung Neoplasms 108 Liver Neoplasms 107 Gastrointestinal Neoplasms 98 Melanoma 87 Biliary Tract Neoplasms 77 Prostatic Neoplasms 75 Endometrial Neoplasms 74 Esophageal Squamous Cell Carcinoma 67 Carcinoma, Renal Cell 57 Squamous Cell Carcinoma of Head and Neck 54 Sarcoma 54 Uterine Cervical Neoplasms 51 Adenocarcinoma Of Esophagus 47 Head and Neck Neoplasms 46 Urinary Bladder Neoplasms 42 Triple Negative Breast Neoplasms 39 Anus Neoplasms 36

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × Gastrointestinal × 90 days × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡